Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
$2.04
-$0.05(-2.44%)
At close: 4:00 PM EST
$2.04
-$0.05(-2.44%)
Day’s Range― - ―
52-Week Range$1.32 - $3.53
Previous CloseN/A
Volume50.42K
Average Volume (3M)1.25M
Market Cap
$395.64M
Enterprise Value$155.08M
Total Cash (Recent Filing)$129.69M
Total Debt (Recent Filing)$1.63M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Feb 19, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding147,372,130
10 Day Avg. Volume608,644
30 Day Avg. Volume1,254,006
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue30.75
Enterprise Value/Gross Profit-2.75
Enterprise Value/Ebitda-2.47
Forecast
1Y Price Target
$12.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$15.39M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe pivotal P3 TACTI-004 trial of efti + Keytruda + chemo in 1L NSCLC has enrolled over 170 patients, surpassing the threshold required to trigger a futility analysis.
Revenue And CapitalThe agreement provides validation for efti’s global commercial potential while adding a meaningful source of non-dilutive capital.
Strategic PartnershipsImmutep announced a strategic collaboration and exclusive licensing agreement with Dr. Reddy’s for lead asset Eftilagimod alfa, covering all markets outside North America, Europe, Japan, and Greater China, which sent shares up approximately 30%.
Bears Say
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $395.64M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 19, 2026 which is in 57 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 29, 2025. The company reported -$0.197 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.011.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.18.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.197 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -3.012%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (488.24% Upside)
$12.00 (488.24% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.96%
12-Months-Change
Fundamentals
Return on Equity
-35.86%
Trailing 12-Months
Asset Growth
-23.58%
Trailing 12-Months
Company Description
Immutep
Immutep (IMMP) is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company operates primarily in the healthcare sector and specializes in harnessing the power of the immune system to combat various diseases. Its core products include LAG-3 (Lymphocyte Activation Gene-3) related therapies, which are designed to enhance immune response in patients undergoing treatment for cancers such as melanoma and breast cancer, as well as autoimmune conditions.
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(488.24% Upside)
Technical Analysis
Cellectis SA
―
Cartesian Therapeutics
―
I-MAB
―
Silence Therapeutics
―
Lyell Immunopharma
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.51% Other Institutional Investors
98.95% Public Companies and
Individual Investors